Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria

被引:32
作者
Diekmann, Fritz [1 ,2 ]
Budde, Klemens [1 ]
Slowinski, Torsten [1 ]
Oppenheimer, Federico [2 ]
Fritsche, Lutz [1 ]
Neumayer, Hans H. [1 ]
Campistol, Josep M. [2 ]
机构
[1] Charite Campus Mitte, Dept Nephrol, D-10117 Berlin, Germany
[2] Hosp Clin Barcelona, Dept Nephrol & Renal Transplantat, Barcelona, Spain
关键词
calcineurin inhibitor; chronic allograft dysfunction; mammalian target of rapamycin inhibitor; proteinuria; rapamycin; sirolimus; toxicity;
D O I
10.1111/j.1432-2277.2007.00592.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
The aim was to evaluate long-term graft survival and function after conversion to sirolimus (SRL) for chronic calcineurin inhibitor (CNI) toxicity and the predictive value of baseline proteinuria. This is a follow-up conversion study of 59 renal transplant patients with deteriorating graft function and histologic signs of CNI toxicity. Previously, baseline proteinuria <800 mg/day was identified as a short-term predictor for successful conversion. Follow-up was 5.3 +/- 0.8 (3.7-6.8) years. Patient survival was 88%, graft survival 38%. Creatinine clearance at the last follow-up was 33.7 +/- 14 ml/min, proteinuria 826 +/- 860mg/day. Baseline proteinuria <800 mg/day was associated with better graft survival. In a cox analysis including proteinuria >800 mg, glomerular filtration rate, age at conversion, chronic Banff score at conversion and time after transplantation at conversion, higher proteinuria was associated with a relative risk of graft loss of 3.98. Prognosis of chronic allograft dysfunction is poor. However, conversion to SRL remains an option for patients with low baseline proteinuria, which can slow down deterioration of graft function during a follow-up period of up to 5 years.
引用
收藏
页码:152 / 155
页数:4
相关论文
共 10 条
[1]   Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus [J].
Bumbea, V ;
Kamar, N ;
Ribes, D ;
Esposito, L ;
Modesto, A ;
Guitard, J ;
Nasou, G ;
Durand, D ;
Rostaing, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) :2517-2523
[2]   Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction [J].
Diekmann, F ;
Budde, K ;
Oppenheimer, F ;
Fritsche, L ;
Neumayer, HH ;
Campistol, JM .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1869-1875
[3]   Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study [J].
Dudley, C ;
Pohanka, E ;
Riad, H ;
Dedochova, J ;
Wijngaard, P ;
Sutter, C ;
Silva, HT .
TRANSPLANTATION, 2005, 79 (04) :466-475
[4]  
Meier-Kriesche HU, 2004, AM J TRANSPLANT, V4, P1289, DOI 10.1111/j.1600-6143.2004.00515.x
[5]   Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience [J].
Morelon, E ;
Kreis, H .
TRANSPLANTATION PROCEEDINGS, 2003, 35 (3A) :52S-57S
[6]  
Nankivell Brian J., 2003, New England Journal of Medicine, V349, P2326, DOI 10.1056/NEJMoa020009
[7]   Medical progress - Strategies to improve long-term outcomes after renal transplantation [J].
Pascual, M ;
Theruvath, T ;
Kawai, T ;
Tolkoff-Rubin, N ;
Cosimi, AB .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (08) :580-590
[8]   Conversion from cyclosporine to sirolimus in stable renal transplant recipients [J].
Sennesael, JJ ;
Bosmans, JL ;
Bogers, JP ;
Verbeelen, D ;
Verpooten, GA .
TRANSPLANTATION, 2005, 80 (11) :1578-1585
[9]   A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation [J].
Watson, CJE ;
Firth, J ;
Williams, PF ;
Bradley, JR ;
Pritchard, N ;
Chaudhry, A ;
Smith, JC ;
Palmer, CR ;
Bradley, JA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (10) :2496-2503
[10]  
2006, TRANSPLANTATION S2, V82, P412